




①. ②
3-16-92
8/1/92
Chen

UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Atty's Docket: WALLACH=4
WALLACH et al.)	Art Unit: 1814 ✓
Serial No.: 07/625,668)	Examiner: Bugaisky, G.
Filed: December 13, 1990)	January 14, 1992
For: EXPRESSION OF THE)	Washington, D.C.
RECOMBINANT TUMOR)	
NECROSIS FACTOR ...)	

INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231



Sir:

In order to comply with discretionary regulations 37 CFR 1.97 and 1.98, attached hereto is a copy of Form PTO-1449 and copies¹ of the documents listed thereon. These documents contain information which the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent.

The attached documents are all mentioned in the present specification and a brief description of relevance can be found

¹ To the extent that a document is listed and no copy of same is attached, then such document is not at the present time available to the undersigned or is available in the file of a parent application. If a listed document is not in the English language and an English translation is readily available, such translation is also attached; if translation is not attached, it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then such equivalent patent is also cited on the attached form along with the corresponding foreign language patent and a connecting arrow indicated therebetween; if no such English language equivalent is cited, then none is known to the undersigned.

thereat.


In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on the attached Form PTO-1449, so that it will appear on the face of the patent issuing on the present application, even if the Examiner does not consider it sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with.

The present Disclosure Statement is being submitted in compliance with 37 CFR 1.56 as an Examiner might consider any cited document important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited document(s) represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art, consistent with 37 CFR 1.104(a) and 1.106(b), and in the course of such search will review for relevance every document cited on the attached form even if not initialed.

Early and favorable consideration is earnestly
solicited.

Respectfully submitted,

BROWDY AND NEIMARK

A handwritten signature in dark ink, appearing to read 'S. Neimark', is written over a horizontal line.

Sheridan Neimark
Registration No. 20,520

419 Seventh Street, N.W.
Washington, D.C. 20004
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
RLB:jkh
wallach4.dis